[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610658":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":35,"collaborators":10,"id":39,"slug":10,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":52,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"250 patients with a diagnosis of uterine fibroids who underwent uterine artery embolization",null,"Women diagnosed with symptomatic uterine fibroids who underwent image-guided uterine artery embolization as treatment. No additional surgical or medical interventions were performed during the procedure.",[13],{"name":14,"affiliation":15,"role":16},"Giuseppe Cittadini, MD","IRCCS Ospedale Policlinico San Martino","STUDY_CHAIR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Emanuele Barabino, MD","CONTACT","00393331002778","emanuele.barabino@hsanmartino.it",[24],{"facility":25,"status":10,"city":26,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"IRCCS OSpedale Policlinico San Martino","Genova","16100","Italy",{"type":30,"coordinates":31},"Point",[32,33],11.87211,45.21604,{"lat":33,"lon":32},{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Emanuele Barabino","Emanuele Barabino, MD, EBIR - Principal Investigator","100610658",false,"NCT07230444","Artificial Intelligence for the Intra-procedural Assessment of Uterine Artery Embolization","Validation and Implementation With Artificial Intelligence of Software for the Intra-procedural Assessment of Uterine Artery EMBOlization","AI-EMBO","Inclusion Criteria:\n\n* Female patients ≥18 years\n* Symptomatic uterine fibroids (e.g., bleeding, bulk symptoms, pain)\n* Underwent UAE as definitive therapy\n* Availability of baseline clinical\u002Fimaging data (for retrospective arm) or ability to provide informed consent (for prospective arm)\n\nExclusion Criteria:\n\n* Lack of clinical follow-up\n* Poor quality or incomplete angiographic images.","FEMALE","18 Years","55 Years",{"count":50,"type":51},250,"ESTIMATED","6 Months","OBSERVATIONAL","Uterine artery embolization is a minimally invasive treatment for symptomatic uterine fibroids, but intra-procedural assessment of embolization adequacy currently relies on subjective angiographic criteria. This study evaluates a proprietary angiographic analysis software (AQ-VERO) that extracts quantitative time-to-density perfusion metrics in real time. The study aims to (1) validate the accuracy and reproducibility of AQ-VERO during uterine artery mebolization, and (2) develop an AI-based decision support system using AQ-VERO-derived metrics to improve objective intra-procedural assessment of treatment endpoints.",[56],"Uterine Fibroids (UF)",[58,59,60,61,62],"uterine fibroids","embolization","uterine artery embolization","quantitative imaging","artificial intelligence","NOT_YET_RECRUITING","2025-11-15",{"date":66,"type":67},"2025-11-19","ACTUAL",{"date":69,"type":51},"2025-12-01",{"date":71,"type":51},"2027-05-31",{"name":37,"class":6},1]